Pomerantz Appointed Co-Lead Counsel in NRx Pharmaceuticals Securities Litigation

On April 6, 2022, U.S. District Judge Maryellen Noreika of the District of Delaware appointed Pomerantz LLP as Co-Lead Counsel on behalf of the Co-Lead Plaintiff, and the class, in NRx Pharmaceuticals, Inc., 1:22-cv-00066-MN (D. Del.). This securities action alleges that NRx Pharmaceuticals, Inc. misrepresented the efficacy and regulatory prospects of ZYESAMI (also known as aviptadil), its investigational pre-commercial drug for the treatment COVID-19 related respiratory failure. NRx is a clinical-stage pharmaceutical company that develops various therapeutics for the treatment of central nervous system disorders and the treatment and prevention…